- Conditions
- Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Refractory Secondary Acute Myeloid Leukemia
- Interventions
- Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Fludarabine Phosphate, Melphalan, Multigated Acquisition Scan, Palifermin, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Sirolimus, Tacrolimus, Total Marrow and Lymphoid Irradiation
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 985–1008
of 17,257
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Fludarabine monophosphate, melphalan, Bortezomib
- Drug
- Lead sponsor
- Hackensack Meridian Health
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Hackensack, New Jersey
- Conditions
- Chronic Kidney Disease
- Interventions
- Zibotentan, Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 542 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 50
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Downey, California + 44 more
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes
- Interventions
- Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine, Phase 2 - OXi4503 + cytarabine
- Drug
- Lead sponsor
- Mateon Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Gainesville, Florida • Miami, Florida + 1 more
- Conditions
- Neuroendocrine Tumors
- Interventions
- AlphaMedix
- Drug
- Lead sponsor
- Orano Med LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Tampa, Florida • Metairie, Louisiana + 1 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Ipilimumab, Radiotherapy (IMRT or 3-D CRT)
- Drug · Radiation
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Polycythemia Vera
- Interventions
- P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101)
- Drug
- Lead sponsor
- PharmaEssentia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Jacksonville, Florida • Fort Wayne, Indiana • Westwood, Kansas + 14 more
- Conditions
- Hepatitis B, Chronic
- Interventions
- JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, Tenofovir alafenamide, JNJ-56136379
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Pittsburgh, Pennsylvania • Seattle, Washington
- Conditions
- Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
- Interventions
- Rozanolixizumab, Placebo
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BMS-512148, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 5
- States / cities
- Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 2 more
- Conditions
- Leukemia, Lymphoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- estramustine phosphate sodium, paclitaxel, vinorelbine ditartrate
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Asthma Patients
- Interventions
- AZD1981, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 19
- States / cities
- Fullerton, California • Los Angeles, California • Mission Viejo, California + 16 more
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Bimekizumab, Adalimumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Povetacicept, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 15
- States / cities
- Mission Hills, California • Boca Raton, Florida • Homestead, Florida + 10 more
- Conditions
- Breast Cancer
- Interventions
- filgrastim, CMF regimen, docetaxel, doxorubicin hydrochloride, tamoxifen citrate, autologous bone marrow transplantation, surgical procedure, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2013
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Relatlimab, Nivolumab, Bevacizumab, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 5 more
- Conditions
- Ovarian Cancer, Cognitive Impairment
- Interventions
- N-Acetyl-Cysteine, Placebo
- Drug · Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Moderate-to-Severe Asthma
- Interventions
- Anti-GM-CSF Monoclonal Antibody 400mg, Placebo
- Biological · Other
- Lead sponsor
- Humanigen, Inc.
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Fullerton, California • Granada Hills, California + 27 more
- Conditions
- Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
- Interventions
- Placebo for Linaclotide, Linaclotide
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 5 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 38
- States / cities
- Foley, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 33 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- rivogenlecleucel, rimiducid, Cyclophosphamide, haplo-HSCT
- Biological · Drug · Procedure
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • San Antonio, Texas
- Conditions
- neurofibromatosis1 (NF1), Recurrent or Progressive Optic Pathway Gliomas (OPG), Recurrent or Progressive Low-grade Glioma
- Interventions
- Sorafenib (Nexavar)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Melanoma
- Interventions
- ipilimumab, nivolumab
- Drug
- Lead sponsor
- Parker Institute for Cancer Immunotherapy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Basking Ridge, New Jersey + 4 more
- Conditions
- Cirrhosis, Liver, Cytopenia
- Interventions
- Danazol Pill
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Squamous Cell Non Small Cell Lung Cancer
- Interventions
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A
- Drug
- Lead sponsor
- GI Innovation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 317 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 3
- States / cities
- New York, New York • Huntersville, North Carolina